Blackhill Capital Inc. Sells 11,771 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Posted by Francis Steltz on Jun 14th, 2026

Blackhill Capital Inc. cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 21.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,079 shares of the medical equipment provider’s stock after selling 11,771 shares during the period. Zimmer Biomet makes up 0.2% of Blackhill Capital Inc.’s investment portfolio, making the stock its 21st biggest holding. Blackhill Capital Inc.’s holdings in Zimmer Biomet were worth $3,784,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ZBH. Main Management ETF Advisors LLC boosted its holdings in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after acquiring an additional 112 shares during the period. Boltwood Capital Management boosted its holdings in Zimmer Biomet by 3.9% during the fourth quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock valued at $348,000 after acquiring an additional 144 shares during the period. Independence Bank of Kentucky boosted its holdings in Zimmer Biomet by 9.7% during the fourth quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock valued at $147,000 after acquiring an additional 145 shares during the period. LOM Asset Management Ltd boosted its holdings in Zimmer Biomet by 21.5% during the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock valued at $75,000 after acquiring an additional 147 shares during the period. Finally, Mesirow Financial Investment Management Inc. boosted its holdings in Zimmer Biomet by 5.9% during the third quarter. Mesirow Financial Investment Management Inc. now owns 2,723 shares of the medical equipment provider’s stock valued at $268,000 after acquiring an additional 151 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 1.6%

NYSE ZBH opened at $88.54 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The firm has a 50-day simple moving average of $87.56 and a 200 day simple moving average of $90.43. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The stock has a market cap of $17.13 billion, a PE ratio of 23.00, a PEG ratio of 2.05 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same quarter last year, the company earned $1.81 earnings per share. The firm’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.28% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, April 7th. Citizens Jmp decreased their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a report on Wednesday, April 29th. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $102.70.

View Our Latest Stock Analysis on ZBH

About Zimmer Biomet

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.